Pinteon Therapeutics Announces First Patient Dosed in Phase 1 Study of PNT001 in Patients with Acute Traumatic Brain Injury

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pinteon Therapeutics, a biotechnology company focused on protecting neuronal health by targeting neurotoxic forms of tau, today announced that the first patient has been dosed in a Phase 1b multiple ascending dose study evaluating PNT001, a novel tau antibody that uniquely targets a toxic epitope known to drive neurodegenerative disease, in patients with acute traumatic brain injury (TBI).

“Millions of emergency room visits, hospitalizations and deaths related to traumatic brain injury occur every year in the U.S., and patients may endure months or years of physical, emotional and cognitive effects, even after a single mild injury,” said Larry Altstiel, M.D., Ph.D, Pinteon’s chief medical officer. “Based on preclinical and human data, as well as promising safety results from our study of PNT001 in healthy volunteers, we believe our investigational therapy has the potential to block the spread of neurotoxic tau observed in traumatic brain injury. We look forward to evaluating the potential of PNT001 for this important unmet medical need.”

The randomized, double-blind, placebo-controlled multiple ascending dose study will enroll 64 patients across two dose level cohorts that, based on the Phase 1 study in healthy volunteers, will provide potentially therapeutic cerebrospinal fluid concentrations of PNT001. Patients will be randomized to receive three monthly intravenous doses of PNT001 or placebo, and will receive their first dose within 24 hours of documented traumatic brain injury. Safety, tolerability, pharmacokinetic, biomarker, imaging and cognitive data will be collected over 12 weeks. More information about the study can be found on ClinicalTrials.gov (NCT04677829).

About Pinteon Therapeutics

Pinteon Therapeutics is advancing clinical studies of a novel antibody that aims to interrupt the spread of toxic tau and protect and preserve brain function in patients with neurodegenerative disease. Pinteon’s lead asset, PNT001, is the only antibody in development that targets cis-pT231 tau, a neurotoxic epitope that has been identified in multiple preclinical studies as a potent driver of neurodegenerative disease. The company reported promising Phase 1 safety data early in 2021 showing PNT001 was well-tolerated at dose levels that may provide potential therapeutic effect. Pinteon is led by an experienced management team with strong track records in CNS drug discovery and development and is funded by Morningside Ventures. For more information, visit pinteon.com.

Lisa Qu
Ten Bridge Communications
lqu@tenbridgecommunications.com
678-662-9166